Orange Book product · Generic (ANDA)
NEVIRAPINE
NEVIRAPINE
At a glance
May 22, 2012
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 22, 2012
14 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
NEVIRAPINE
Strength
200MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 203080
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of NEVIRAPINE
- 2012VIRAMUNE XRBrand (NDA)
NDA 201152 · BOEHRINGER INGELHEIM
- 1998VIRAMUNEBrand (NDA)
NDA 020933 · BOEHRINGER INGELHEIM
- 1996VIRAMUNEBrand (NDA)
NDA 020636 · BOEHRINGER INGELHEIM
- 2019NEVIRAPINEGeneric (ANDA)
ANDA 090688 · MACLEODS PHARMS LTD
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 206879 · MACLEODS PHARMS LTD
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207684 · CIPLA
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207467 · TECH ORGANIZED
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207698 · AUROBINDO PHARMA
- 2016NEVIRAPINEGeneric (ANDA)
ANDA 208616 · AUROBINDO PHARMA
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 204621 · ALVOGEN
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206271 · PHARMOBEDIENT
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206448 · CIPLA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
